Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27472295 | 0.85 | TAAR1 (0.50) | TAAR1ALDH1A1IGF1RALOX15KCNH2 | |
| SCHEMBL31500447 | 0.84 | TAAR1 (0.54) | TAAR1ALDH1A1KCNH2 | |
| SCHEMBL2353922 | 0.84 | TAAR1 (0.54) | TAAR1ALDH1A1KCNH2 | |
| SCHEMBL6546881 | 0.82 | TAAR1 (0.65) | TAAR1GPR84LMNAALDH1A1 | |
| SCHEMBL13276099 | 0.81 | TAAR1 (0.47) | TAAR1ALDH1A1 | |
| SCHEMBL9799345 | 0.81 | MAOB (0.57) | TAAR1 | |
| SCHEMBL11303064 | 0.80 | MAPK1 (0.47) | TAAR1KDM4ELMNATHRBNPC1 | |
| SCHEMBL6546802 | 0.79 | TAAR1 (0.52) | TAAR1ALDH1A1 | |
| SCHEMBL2302649 | 0.78 | KMT2A (0.50) | TAAR1GPR84LMNANPC1RAB9A | |
| SCHEMBL29979642 | 0.78 | SIGMAR1 (0.47) | TAAR1GPR84ALDH1A1IGF1RALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438989-B1 | USE OF ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-9061959-B2 | Method for manufacturing optically active menthol | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-06-23 | — | — | US | disclosed |
| EP-2647616-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL | Takasago International Corporation (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130253228-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-26 | — | — | US | disclosed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
| CN-1131235-C | 11 beta-halogen-7 alpha-substituted estratrienes, method for producing pharmaceutical preparations containing said 11 beta-halogen-7 alpha-substituted estratrienes, and use of said substances for producing medicaments | SCHERING AG (DE) | 2003-12-17 | — | — | CN | disclosed |
| CN-1286693-A | 11 'beta'-halogen-7 'alpha'-substd estratrienes, method for producing pharmaceutical preparations contg. said 11 'beta'-halogen-7 'alpha'-substd estratrienes and use of same for producing medicaments | SCHERING AG (DE) | 2001-03-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | TAAR1 2410/4885GPR84 3850/4885KDM4E 4195/4885 |
| US-20130253228-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL | MSMO1, GGPS1, MAN1B1 | TAAR1 2809/4885GPR84 2884/4885KDM4E 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.